CLINICAL TRIALS PROFILE FOR DITROPAN

All Clinical Trials for Ditropan

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00269750 ↗	A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.	Completed	Alza Corporation, DE, USA	Phase 3	1996-07-01	The purpose of this study is to compare the efficacy and safety of OROS® oxybutynin to that of Ditropan® (immediate-release oxybutynin) for the treatment of patients with urge or mixed urinary incontinence. Oxybutynin is an antispasmodic, anticholinergic medication for the treatment of the symptoms of overactive bladder.
NCT00293839 ↗	Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder	Completed	Alza Corporation, DE, USA	Phase 3	1969-12-31	The purpose of this study is to compare the efficacy of DITROPAN® XL (oxybutynin chloride) Extended-Release Tablets and DETROL® LA (tolterodine tartrate extended-release capsules) in the reduction of urge urinary incontinence episodes during a 12-week treatment period in patients with overactive bladder. The secondary objective is to compare the tolerability of DITROPAN® XL (oxybutynin chloride) and DETROL® LA (tolterodine tartrate) during a 12-week treatment period.
NCT00338624 ↗	An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.	Completed	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Phase 3	2004-05-01	The purpose of this study is to evaluate the safety and effectiveness of oxybutynin extended release tablets 10 mg plus tamsulosin HCl 0.4 mg in the treatment of lower urinary tract symptoms as measured by change of the total International Prostate Symptom Score (I-PSS) from baseline to Week 12 or the Final Visit.
NCT00648843 ↗	Food Study of Oxybutynin Chloride Extended-Release Tablets 5 mg and Ditropan XL® Tablets 5 mg	Completed	Mylan Pharmaceuticals	Phase 1	2002-12-01	The objective of this study was to investigate the single-dose relative bioavailability of Mylan's oxybutynin chloride extended-release tablets to ALZA's Ditropan XL® tablets following an oral, single 20 mg (4 x 5 mg) dose under fed conditions.
NCT00649129 ↗	Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg	Completed	Mylan Pharmaceuticals	Phase 1	2002-07-01	The objective of this study was to investigate the single-dose relative bioavailability of Mylan's oxybutynin chloride extended-release tablets to ALZA's Ditropan XL® tablets following an oral, single 20 mg (2 x 10 mg) dose under fasting conditions.
NCT00649259 ↗	Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg	Completed	Mylan Pharmaceuticals	Phase 1	2002-10-01	The objective of this study was to investigate the single-dose relative bioavailability of Mylan's oxybutynin chloride extended-release tablets to ALZA's Ditropan XL® tablets following an oral, single 20 mg (2 x 10 mg) dose under fed conditions.
NCT00649272 ↗	Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg	Completed	Mylan Pharmaceuticals	Phase 1	2006-01-01	The objective of this study was to investigate the bioequivalence of Oxybutynin Chloride Extended-Release Tablets, 15 mg (Mylan Pharmaceuticals Inc.) to Ditropan XL® Extended- Release Tablets, 15 mg (ALZA Corporation; Distributed and marketed by: Ortho-McNeil Pharmaceuticals Inc.) following a single, oral 15 mg dose (1 x 15 mg tablet) under fasting conditions.

Clinical Trial Conditions for Ditropan

Condition Name

Condition Name for Ditropan
Intervention	Trials
Healthy	6
Overactive Bladder	6
Hot Flashes	2
Ductal Breast Carcinoma In Situ	1

Condition MeSH

Condition MeSH for Ditropan
Intervention	Trials
Urinary Bladder, Overactive	7
Urinary Incontinence	3
Enuresis	3
Hot Flashes	2

Clinical Trial Locations for Ditropan

Trials by Country

Trials by Country for Ditropan
Location	Trials
United States	21
Canada	3
Korea, Republic of	1
Iran, Islamic Republic of	1

Trials by US State

Trials by US State for Ditropan
Location	Trials
West Virginia	3
North Dakota	3
North Carolina	1
Missouri	1
Minnesota	1

Clinical Trial Progress for Ditropan

Clinical Trial Phase

Clinical Trial Phase for Ditropan
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	8
Phase 2	6

Clinical Trial Status

Clinical Trial Status for Ditropan
Clinical Trial Phase	Trials
Completed	16
Recruiting	3
Unknown status	1

Clinical Trial Sponsors for Ditropan

Sponsor Name

Sponsor Name for Ditropan
Sponsor	Trials
Mylan Pharmaceuticals	6
Pfizer	3
Stéphane Bolduc	2

Sponsor Type

Sponsor Type for Ditropan
Sponsor	Trials
Industry	16
Other	11
NIH	1